These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25846209)

  • 1. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients.
    Nony E; Bouley J; Le Mignon M; Lemoine P; Jain K; Horiot S; Mascarell L; Pallardy M; Vincentelli R; Leone P; Roussel A; Batard T; Abiteboul K; Robin B; de Beaumont O; Arvidsson M; Rak S; Moingeon P
    Allergy; 2015 Jul; 70(7):795-804. PubMed ID: 25846209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy.
    Kinaciyan T; Nagl B; Faustmann S; Frommlet F; Kopp S; Wolkersdorfer M; Wöhrl S; Bastl K; Huber H; Berger U; Bohle B
    J Allergy Clin Immunol; 2018 Mar; 141(3):1002-1008. PubMed ID: 28870463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
    Larenas-Linnemann D
    Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma.
    Tourdot S; Airouche S; Berjont N; Moussu H; Betbeder D; Nony E; Bordas-Le Floch V; Baron-Bodo V; Mascarell L; Moingeon P
    Vaccine; 2013 May; 31(23):2628-37. PubMed ID: 23583462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
    Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
    J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
    Pfaar O; Bachert C; Kuna P; Panzner P; Džupinová M; Klimek L; van Nimwegen MJ; Boot JD; Yu D; Opstelten DJE; de Kam PJ
    J Allergy Clin Immunol; 2019 Mar; 143(3):970-977. PubMed ID: 30508538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis.
    Mäkelä MJ; Gyllfors P; Valovirta E; Steffensen MA; Grønager PM; Savolainen J; Winther L
    Clin Ther; 2018 Apr; 40(4):574-586.e4. PubMed ID: 29551533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
    Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
    Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.
    Batard T; Didierlaurent A; Chabre H; Mothes N; Bussières L; Bohle B; Couret MN; Ball T; Lemoine P; Focks Tejkl M; Chenal A; Clément G; Dupont F; Valent P; Krauth MT; André C; Valenta R; Moingeon P
    Int Arch Allergy Immunol; 2005 Mar; 136(3):239-49. PubMed ID: 15722633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model.
    Siebeneicher S; Reuter S; Wangorsch A; Krause M; Foetisch K; Heinz A; Naito S; Reuter A; Taube C; Vieths S; Scheurer S; Toda M
    Allergy; 2015 Dec; 70(12):1559-68. PubMed ID: 26304061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
    Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
    Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
    J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.
    Vrtala S; Fohr M; Campana R; Baumgartner C; Valent P; Valenta R
    Vaccine; 2011 Mar; 29(11):2140-8. PubMed ID: 21215346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
    Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
    J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.
    Campana R; Moritz K; Marth K; Neubauer A; Huber H; Henning R; Blatt K; Hoermann G; Brodie TM; Kaider A; Valent P; Sallusto F; Wöhrl S; Valenta R
    J Allergy Clin Immunol; 2016 Feb; 137(2):601-609.e8. PubMed ID: 26518092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
    Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
    Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber.
    Meyer W; Narkus A; Salapatek AM; Häfner D
    Allergy; 2013 Jun; 68(6):724-31. PubMed ID: 23621350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality and potency profile of eight recombinant isoallergens, largely mimicking total Bet v 1-specific IgE binding of birch pollen.
    Seutter von Loetzen C; Reuter A; Spiric J; Schulenborg T; Bellinghausen I; Völker E; Vogel L; Rösch P; Schiller D
    Clin Exp Allergy; 2019 May; 49(5):712-723. PubMed ID: 30706562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant marker allergens in diagnosis of patients with allergic rhinoconjunctivitis to tree and grass pollens.
    Canis M; Gröger M; Becker S; Klemens C; Kramer MF
    Am J Rhinol Allergy; 2011; 25(1):36-9. PubMed ID: 21711974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.
    Shirasaki H; Yamamoto T; Koyanagi Y; Watanabe N; Himi T
    Allergol Int; 2008 Mar; 57(1):93-6. PubMed ID: 18209509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.